"Our goal is to develop one successful candidate molecule for each year of the grant that can be offered to patients in order to turn the tables on pancreatic cancer," Daniel Von Hoff, director of TGen's Translational Drug Development Division and the grant's principal investigator, said in a statement.
The funding will be applied to three related projects, TGen said. Its collaborators include the Arizona Cancer Center at the University of Arizona and the University of Texas M.D. Anderson Cancer Center, the institute said.
TGen's Cancer Drug Development Laboratory will use siRNA as an adjuvant therapy, and to identify additional drug targets and biomarkers. Researchers at University of Texas MD Anderson Cancer Center will test drugs to change tumor micro-environments in order to prevent growth. A project conducted at TGen aims to produce drugs that selectively kill tumor cells having genomic deletions.
Approximately 35,000 people in the US will be diagnosed with pancreatic cancer this year and 31,800 people will die, TGen said.